Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs

References

• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-3105.
   PubMed Web of Science ®Google Scholar
• Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005;65(16):2379-2404.
   PubMedGoogle Scholar
• Bloom BS. Prevalence and economic effects of depression. Manag Care 2004;13(6 Suppl):9-16.
   PubMedGoogle Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64(12):1465-1475.
   PubMedGoogle Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. Current perspectives on the diagnosis and treatment of major depressive disorder. Am J Manag Care 2001;7(11 Suppl):S353-366.
   Google Scholar
• Anonymous. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157(4 Suppl):1-45.
   Google Scholar
• Weilburg JB. An overview of SSRI and SNRI therapies for depression. Manag Care 2004;13(6 Suppl):25-33.
   PubMedGoogle Scholar
• Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006;21(3):159-169.
   PubMedGoogle Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65(9):1190-1196.
   PubMed Web of Science ®Google Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psycho-pharmacol 2004;19(5):305-310.
   PubMedGoogle Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7(4 Suppl 1):40-44.
   Google Scholar
• Hirschfeld RM, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004;65(4 Suppl):46-52.
   PubMedGoogle Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31(2):122-131.
   PubMedGoogle Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19(3):149-155.
   PubMedGoogle Scholar
• Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59(3):268-275.
   PubMedGoogle Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50(1):57-64.
   PubMedGoogle Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20(3):131-137.
   PubMedGoogle Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23(7):1605-1614.
   PubMedGoogle Scholar
• Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21(5):297-309.
   PubMed Web of Science ®Google Scholar
• Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs 2004;18(7):469-473
   PubMedGoogle Scholar
• Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27(1):111-124.
   PubMedGoogle Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin. Jun 2004;20(6):869-878.
   PubMedGoogle Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18(13):911-932.
   PubMedGoogle Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21(4):631-642.
   PubMedGoogle Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23(2):155-167
   PubMedGoogle Scholar
• Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998;47(6):446-452.
   PubMedGoogle Scholar
• Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care 1996;2:1239-1246.
   Google Scholar
• Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23(7):934-942.
   PubMed Web of Science ®Google Scholar
• de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63(4):619-630.
   PubMedGoogle Scholar
• Simon GE, Katon WJ, Lin EH, et al. Diabetes complications and depression as predictors of health service costs. Gen Hosp Psychiatry 2005;27(5):344-351.
   PubMedGoogle Scholar
• Kalsekar ID, Madhavan SM, Amonkar MM, et al. The effect of depression on healthcare utilization and costs in patients with type 2 diabetes. Manag Care Interface 2006;19(3):39-46.
   PubMedGoogle Scholar
• The International Classification of Diseases, 9th Revision, Clinical Modification. 4 edn. Washington, DC: The U.S. Department of Health and Human Services, 1991.
   Google Scholar
• McCombs JS, Luo M, Johnstone BM, Shi L. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000;3(3):222-231.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613-619.
   PubMed Web of Science ®Google Scholar
• Anonymous. Patient compliance in depression. Am J Manag Care 2000;6(2 Suppl):S31-38.
   Google Scholar
• Wu E, Greenberg P, Yang E, et al. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin 2008;24(10):2805-2813.
   PubMedGoogle Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005;27(4):486-496.
   PubMedGoogle Scholar
• Burton WN, Chen CY, Conti DJ, et al. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care 2007;13(2):105-112.
   PubMedGoogle Scholar
• Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40(7-8):1280-1288.
   PubMedGoogle Scholar
• Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care 2000;38(9):911-925.
   PubMedGoogle Scholar
• Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141(1 Suppl):S28-33
   Google Scholar